非维生素K拮抗剂口服抗凝药相关脑出血的特征
本研究为多中心观察性队列研究,整合1328例口服抗凝药相关脑出血患者数据,其中190例为NOAC相关。结果显示NOAC与VKA相关脑出血在基线血肿体积、血肿扩大率及3个月不良功能结局方面无显著差异;亚组分析提示存在临床相关抗凝活性时血肿扩大和脑室出血比例更高。
要点
- NOAC与VKA相关脑出血的血肿特征及3个月功能结局无显著差异。
- 存在临床相关抗凝活性时,脑室出血和血肿扩大比例更高。
- NOAC药物类型或剂量方案未导致影像特征或结局的显著差异。
核心结论
- 在有效抗凝情况下,NOAC与VKA相关脑出血的血肿特征和功能结局无差异。
研究设计与样本
- 多中心观察性队列研究,整合2011至2015年德国19家三级中心1328例口服抗凝药相关脑出血患者的个体数据,其中NOAC相关190例。
主要发现
- 基线血肿体积中位数NOAC组14.7 mL,VKA组16.4 mL,P=0.33。
- 血肿扩大率NOAC组33.6%(49/146),VKA组34.2%(235/688),P=0.89。
- 3个月不良结局(mRS 4-6)比例NOAC组70.4%(126/179),VKA组69.4%(473/682),P=0.79。
- 存在临床相关抗凝活性者脑室出血比例47.7%(52/109)对25.7%(9/35),P=0.022。
- 存在临床相关抗凝活性者血肿扩大比例38.9%(35/90)对16.7%(5/30),P=0.040。
临床怎么用
- 对于NOAC或VKA相关脑出血患者,可参照相似的血肿特征和功能结局进行预后评估。
- 评估NOAC相关脑出血时,需关注是否存在临床相关抗凝活性,因其与更高的脑室出血和血肿扩大风险相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Given inconclusive studies, it is debated whether clinical and imaging characteristics, as well as functional outcome, differ among patients with intracerebral hemorrhage (ICH) related to vitamin K antagonists (VKA) versus non-vitamin K antagonist (NOAC)-related ICH. Notably, clinical characteristics according to different NOAC agents and dosages are not established. Methods- Multicenter observational cohort study integrating individual patient data of 1328 patients with oral anticoagulation-associated ICH, including 190 NOAC-related ICH patients, recruited from 2011 to 2015 at 19 tertiary centers across Germany. Imaging, clinical characteristics, and 3-months modified Rankin Scale (mRS) outcomes were compared in NOAC- versus VKA-related ICH patients. Propensity score matching was conducted to adjust for clinically relevant differences in baseline parameters. Subgroup analyses were performed regarding NOAC agent, dosing and present clinically relevant anticoagulatory activity (last intake <12h/24h or NOAC level >30 ng/mL). Results- Despite older age in NOAC patients, there were no relevant differences in clinical and hematoma characteristics between NOAC- and VKA-related ICH regarding baseline hematoma volume (median [interquartile range]: NOAC, 14.7 [5.1-42.3] mL versus VKA, 16.4 [5.8-40.6] mL; P=0.33), rate of hematoma expansion (NOAC, 49/146 [33.6%] versus VKA, 235/688 [34.2%]; P=0.89), and the proportion of patients with unfavorable outcome at 3 months (mRS, 4-6: NOAC 126/179 [70.4%] versus VKA 473/682 [69.4%]; P=0.79). Subgroup analyses revealed that NOAC patients with clinically relevant anticoagulatory effect had higher rates of intraventricular hemorrhage (n/N [%]: present 52/109 [47.7%] versus absent 9/35 [25.7%]; P=0.022) and hematoma expansion (present 35/90 [38.9%] versus absent 5/30 [16.7%]; P=0.040), whereas type of NOAC agent or different NOAC-dosing regimens did not result in relevant differences in imaging characteristics or outcome. Conclusions- If effectively anticoagulated, there are no differences in hematoma characteristics and functional outcome among patients with NOAC- or VKA-related ICH. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT03093233.
引用
- Gerner ST, Kuramatsu JB, Sembill JA, et al. Characteristics in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage. Stroke. 2019. PMID: 31092170. doi:10.1161/STROKEAHA.118.023492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。